The release of extracellular vesicles, whether MVs
Introduction
MVs (microvesicles) are released from the plasma membrane as a result of surface budding. As reviewed previously [1] , Ca 2 + -mediated activation of calpain and ensuing actin cytoskeleton cleavage, together with an inability to maintain the asymmetry of the lipid bilayer, result in the release of MVs 100-1000 nm in diameter. They may be released from mammalian host cells as well as various pathogens, including protozoan parasites [2] . Elucidation of the mechanisms by which intracellular pathogens infect the protective environment of cells where they replicate is essential for developing effective treatments. In the present review, we summarize some of the mechanisms that host and pathogen-derived MVs (as opposed to exosomes) (especially those from the intracellular protozoan pathogen Trypanosoma cruzi) use to either evade immune effector mechanisms or to enhance invasion.
MV-mediated escape from complement-mediated lysis and phagocytosis
The main obstacle to invasion by infectious pathogens is the approximately 20 serum proteins comprising the human complement system which are activated by certain proteins or carbohydrates on invading pathogens [3] . Complement is activated by the classical pathway through antigen-antibody interaction on the pathogen, the associated C1 complex (C1q-r2s2) forming the C3 convertase (C4b2a) through cleavage of C2 and C4. When carbohydrates are recognized on pathogens by MBL (mannan-binding lectin), and L-and H-ficolins, the lectin pathway is activated, this time with the associated MASP-2 (MBL-associated serine protease 2) forming the C3 convertase once more through cleavage of C4 and C2. When C3b binds directly to the pathogen, together with the associated Factor B, this forms the alternative C3 convertase (C3bBb) [3] .
The release of EVs (extracellular vesicles) (comprising exosomes and MVs) provides cells with a mechanism for shedding molecules essential for establishing apoptosis such as caspase 3. We have recently described MV release from the infectious MTr (metacyclic trypomastigote) form of Trypanosoma cruzi [2] . In these experiments, PKH67-labelled human monocytes and PKH26-labelled parasites were cocultured and, whereas 29% of the released MVs were found to be monocyte-derived (stained with PKH67), only 5% were parasite-derived (stained with PKH26). This may be sufficient to enable the parasite to evade complementmediated lysis by removing deposited MAC (membraneattack complex) from the plasma membrane [4] (Figure 1 , steps a and b). Another benefit to pathogens of EV release, especially PS (phosphatidylserine)-rich MVs, is that, by removing PS from the pathogen, a signal promoting phagocytosis is thereby being reduced. In this way, parasitederived EVs could act as decoys (Figure 1 , step c) to evade phagocytosis of the parasite (Figure 1, step d) . Furthermore, host-derived MVs by mimicking host cells could act as decoys ( Figure 1 , step e), thereby inhibiting parasite invasion of host cells ( Figure 1 , step f) using a similar mechanism to that we In other work, MVs from Giardia intestinalis, an intestinal parasite that causes diarrhoea, were able to enhance its attachment to Caco-2 cells, an intestinal epithelial cell line (I. Evans-Osses, E.A. Ansa-Addo, J.M. Inal and M.I. Ramirez, unpublished work). This important finding may be highly relevant to the pathologic potential of Giardia because the trophozoite stage adheres to the microvilli of the epithelial cells of the small intestine [6] .
Role of Ca 2 + channels and, by implication, MVs in the invasion of mammalian cells by intracellular pathogens
Whereas L-type Ca 2 + channels and the levels of intracellular Ca 2 + are important in establishing EV release [7, 8] , stimulated cells pre-treated with the Ca 2 + chelator EGTA lose the capacity to microvesiculate. Interestingly, cells treated with the L-type Ca 2 + blockers nifedipine or verapamil are less able to be invaded by intracellular pathogens [9, 10] , although, in these studies, this was not related to microvesiculation. Intracellular Ca 2 + levels and microvesiculation are likely to be related because raised cytosolic Ca 2 + causes rearrangement of the actin cytoskeleton which is concomitant with a release of MVs. It is also well established that reorganization of the host cell cytoskeleton occurs during pathogen invasion. Bacteria such as Salmonella enterica serovar Typhimurium and Shigella spp. use a 'trigger' mechanism. Through the action of SipA, a bacterial actin-binding protein [11] , Salmonella Typhimurium induces membrane ruffling and actin cytoskeleton remodelling, resulting in uptake. Other intracellular pathogens such Yersinia spp. use a 'zipper' mechanism in which bacterial surface molecule interaction with host cell receptors such as integrins results in activation of host signalling pathways, actin cytoskeleton rearrangement and uptake [12] .
Cell invasion via lipid raft domains
Recent findings in which methylcyclodextrin depletion of cholesterol in cell plasma membranes reduced Mycobacterium bovis and Mycobacterium tuberculosis uptake into macrophages by up to 90% and 85% respectively has shown the importance of cholesterol in mediating the entry of Mycobacterium spp. into macrophages [13] . These findings prompted further research on the role of lipid rafts, which contain cholesterol in infection.
Lipid raft domains are regions of the cell's plasma membrane mainly composed of phospholipids, (glyco)-sphingolipids and cholesterol. Although the size of rafts and their half-life remain uncertain, our best estimate is that raft domains are small (26-70 nm in diameter), carrying only a few proteins and that their half-life ranges from milliseconds to minutes [14] . Some pathogens exploit host lipid rafts to cross the plasma membrane, thereby avoiding antigen presentation by target cells [15, 16] . The recruitment of rafts seems to be a general mechanism employed by microorganisms for infecting cells. By way of example, HIV-1 uses lipid rafts for many purposes, including passage across host cell mucosa [17] , infection production after entry of virus into host immune cells [18] , subversion of host cell signalling for evasion of immunity and replication of virus [19] , exit of the virus from immune cells [20] and dispersal through the vascular system of the host [21] . Bacteria also take advantage of lipid rafts to mediate host cell entry [22, 23] . These are preferred sites because they are sorting areas distributing proteins, for example to the apical side of epithelial cells [24] , thus making them more accessible for entry. The advantage to pathogen entry through raft domains is two-fold. First, in so doing, pathogens can avoid the intracellular degradative pathway and, secondly, they can stimulate signalling pathway leading to membrane ruffling and actin rearrangement in turn leading to cell entry.
Integrins are involved in raft-mediated cell invasion
That the interaction between lipid rafts and the actin cytoskeleton is mediated through integrins has been known for some time [25] . Integrins are heterodimeric cellsurface glycoprotein receptors which mediate intercellular interactions. Integrin binding induced by the clustering of lipid rafts modulates cytoskeleton rearrangement [26] , which leads one to speculate that MVs may also be released during this binding interaction. Indeed, both viral and intracellular bacterial uptake into host cells have increasingly been shown to utilize integrins and integrin-dependent signalling [27] . Many pathogens have evolved ways to adhere to cell-adhesion molecules such as integrins, selectins and Ig receptors that mediate cell-cell and cell-ECM (extracellular matrix) interactions [28] as a means to invade host cells. For example, the interaction between Ipa, a Shigella flexneri protein, with host α5β1 integrin triggers reorganization of the actin cytoskeleton and promotes entry of the bacteria into cells [29] . The implication in much of this work is that the release of MVs is as essential as the assembly of raft microdomains, cholesterol and activation of integrins during the entry of pathogens into mammalian cells. A summary of how T. cruzi may take advantage of MV release to invade the host cell is illustrated in Figure 2 .
MVs and cell invasion by intracellular pathogens
We showed recently that the invasive pathogen T. cruzi can stimulate the release of TGFβ1 (transforming growth factor β1)-bearing MVs which can enhance invasion of host cells [1] . These MVs also carry complement inhibitors which can protect pathogens against complement-mediated lysis in vivo as well as a host of cytokines potentially important in the infective process [30] . We have recently carried out experiments to investigate whether other pathogens also induce MV release. Whereas T. cruzi, an obligate intracellular pathogen, stimulated the release of MVs from several cell types, the extracellular blood-dwelling Trypanosoma brucei did not. The hypothesis that intracellular pathogens induce MV release from host cells, but that extracellular ones do not, was corroborated when it was found that Salmonella enterica serovar Typhi (wild-type, strain SL1344) induced MV release unlike its non-invasive form carrying a deletion in the SPI1 pathogenicity island. Another aspect of microvesiculation and infection by intracellular pathogens not reviewed in the present paper is that of MVs themselves harbouring pathogens, particularly retroviruses. The best example is the so-called Trojan exosome hypothesis which suggests that another type of EV, the exosome, may carry retroviruses, including HIV [31] .
Future directions
Clearly, there is a complex interplay between host-derived and pathogen-derived MVs, all influencing infection which still needs to be elucidated. The initial findings relating to how MVs aid infection, however, are intriguing. If future studies continue to elucidate MV, whether hostderived or pathogen-derived, enhancement of infection, or pathogen-derived MVs enhancing immune evasion, this could point to useful therapeutic approaches. For example, it may be possible to limit microvesiculation whether from infected host cells or pathogen surfaces using pharmacological inhibitors of microvesiculation. As microvesiculation is known to remove drugs from cells, especially cancer cells treated with chemotherapeutic agents [32] , limiting MV release (for example, from host cells harbouring intracellular pathogens) could have the added advantage of rendering pathogens more susceptible to such drugs. A consideration of EVs, whether MVs or exosomes, may also point towards novel vaccination strategies in which preparations of EVs could form the basis of a vaccine. Recently, exosomes from reticulocytes infected with Plasmodium yeolii, for example, were shown to offer protection against challenge infection in mice [33] .
